Physician profile
Avinash M Murthy
NPI 1528228624
$8,098.95
in general payments reported to CMS, 2019-2025
35 companies · $1,151 in 2025
The $1,151 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,742 · 2020: $1,406 · 2021: $491 · 2022: $727 · 2023: $627 · 2024: $956 · 2025: $1,151.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,563 · Travel and Lodging: $170.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,563.39 |
| Travel and Lodging | $169.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,732.97 | 2019-2025 | Avvigo Guidance System, Watchman Access System, Watchman Flx |
| Medtronic Vascular, INC. | $1,335.66 | 2019 | |
| Abiomed | $921.79 | 2019-2025 | Impella |
| Novartis Pharmaceuticals Corporation | $568.83 | 2019-2025 | |
| Philips North America LLC | $375.12 | 2019-2025 | Coronary Other |
| Janssen Pharmaceuticals, INC | $343.56 | 2019-2024 | Xarelto |
| Medtronic, INC. | $338.65 | 2025 | Symplicity G3 |
| Shockwave Medical, INC | $332.94 | 2023-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $230.16 | 2019-2025 | Lifevest |
| Penumbra, INC. | $211.70 | 2021-2023 | Penumbra System |
| United Therapeutics Corporation | $204.69 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $197.12 | 2019-2024 | Jardiance |
| Teleflex LLC | $193.73 | 2023-2025 | Guideliner, Vascband |
| E.R. Squibb & Sons, L.L.C. | $153.34 | 2022-2024 | Camzyos, Eliquis |
| Astrazeneca Pharmaceuticals LP | $145.82 | 2019-2023 | Farxiga |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $108.55 | 2019 | |
| Amgen INC. | $96.25 | 2020-2022 | |
| Pfizer INC. | $91.49 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $79.81 | 2022 | |
| Atricure, INC. | $71.31 | 2024 | |
| Cook Medical LLC | $59.56 | 2019 | |
| Kerecis Limited | $47.92 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Abbott Laboratories | $43.43 | 2019-2024 | Cardiomems |
| Cardiovascular Systems INC. | $42.59 | 2021-2022 | |
| Angiodynamics, INC. | $33.62 | 2023 | Alphavac |
| Biosense Webster, INC. | $31.57 | 2024 | Carto 3 |
| Amarin Pharma, INC. | $21.09 | 2019 | |
| Livanova USA, INC. | $20.15 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $16.85 | 2022 | |
| Ekos Corporation | $13.09 | 2019 | |
| Biomerieux INC | $12.99 | 2023 | |
| Tactile Systems Technology INC | $11.66 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $10.94 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Avinash Murthy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.